Difference between revisions of "Irinotecan (Camptosar)"
m |
m (→References) |
||
Line 64: | Line 64: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
+ | [[Category:Intravenous chemotherapy]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
+ | |||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
Revision as of 23:34, 23 November 2014
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible
single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase
I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bone cancer
- Central nervous system (CNS) cancer
- Cervical cancer
- Colon cancer
- Esophageal cancer
- Pancreatic cancer
- Penile cancer
- Small cell lung cancer
- Unknown primary
Patient drug information
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/14/1996: Initial FDA approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
- 4/20/2000: Colon cancer indication revised:
- Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
- Also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Also known as
Synonyms | ||||
---|---|---|---|---|
Campto Conc | Camptosar | Cloridrato DE Irinotecano | CPT-11 | Elinatecan |
Faultenocan | Irenax | Irinogen | Irinotecan Hydrochloride | Irinotecan Mayne |
Irinotecan Rovi | Irinotel | Irnocam | Itoxaril | Linatecan |
Satigene | Tecnotecan | Topotecin | Trinotecan | Winol |
References
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- Bone cancer medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Cervical cancer medications
- Colon cancer medications
- Esophageal cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Small cell lung cancer medications
- Drugs FDA approved in 1996